CJEU rules out SPCs for new drug formulations, but leaves uncertainty over therapeutic uses

Following the court’s Abraxis decision, life sciences face a more restrictive interpretation of which products qualify for supplementary protection certificates.

Unlock unlimited access to all IAM content